175 related articles for article (PubMed ID: 17366700)
1. HIV integrase: a target for drug discovery.
Lutzke RA; Plasterk RH
Genes Funct; 1997 Dec; 1(5-6):289-307. PubMed ID: 17366700
[TBL] [Abstract][Full Text] [Related]
2. Structure and function of HIV-1 integrase.
Chiu TK; Davies DR
Curr Top Med Chem; 2004; 4(9):965-77. PubMed ID: 15134551
[TBL] [Abstract][Full Text] [Related]
3. Targeting HIV-1 integrase with strand transfer inhibitors.
Li Y; Xuan S; Feng Y; Yan A
Drug Discov Today; 2015 Apr; 20(4):435-49. PubMed ID: 25486307
[TBL] [Abstract][Full Text] [Related]
4. Identification of a small-molecule binding site at the dimer interface of the HIV integrase catalytic domain.
Molteni V; Greenwald J; Rhodes D; Hwang Y; Kwiatkowski W; Bushman FD; Siegel JS; Choe S
Acta Crystallogr D Biol Crystallogr; 2001 Apr; 57(Pt 4):536-44. PubMed ID: 11264582
[TBL] [Abstract][Full Text] [Related]
5. HIV integrase as a target for antiviral chemotherapy.
Nair V
Rev Med Virol; 2002; 12(3):179-93. PubMed ID: 11987143
[TBL] [Abstract][Full Text] [Related]
6. Structure-activity relationships of HIV-1 integrase inhibitors--enzyme-ligand interactions.
Maurin C; Bailly F; Cotelle P
Curr Med Chem; 2003 Sep; 10(18):1795-810. PubMed ID: 12871105
[TBL] [Abstract][Full Text] [Related]
7. Computer tools in the discovery of HIV-1 integrase inhibitors.
Liao C; Nicklaus MC
Future Med Chem; 2010 Jul; 2(7):1123-40. PubMed ID: 21426160
[TBL] [Abstract][Full Text] [Related]
8. Synthesis, biological evaluation and molecular modeling studies of quinolonyl diketo acid derivatives: new structural insight into the HIV-1 integrase inhibition.
Vandurm P; Guiguen A; Cauvin C; Georges B; Le Van K; Michaux C; Cardona C; Mbemba G; Mouscadet JF; Hevesi L; Van Lint C; Wouters J
Eur J Med Chem; 2011 May; 46(5):1749-56. PubMed ID: 21385662
[TBL] [Abstract][Full Text] [Related]
9. Novel inhibitors of HIV integrase: the discovery of potential anti-HIV therapeutic agents.
Nair V
Curr Pharm Des; 2003; 9(31):2553-65. PubMed ID: 14529542
[TBL] [Abstract][Full Text] [Related]
10. Crystal structure of the HIV-1 integrase core domain in complex with sucrose reveals details of an allosteric inhibitory binding site.
Wielens J; Headey SJ; Jeevarajah D; Rhodes DI; Deadman J; Chalmers DK; Scanlon MJ; Parker MW
FEBS Lett; 2010 Apr; 584(8):1455-62. PubMed ID: 20227411
[TBL] [Abstract][Full Text] [Related]
11. A platform for designing HIV integrase inhibitors. Part 2: a two-metal binding model as a potential mechanism of HIV integrase inhibitors.
Kawasuji T; Fuji M; Yoshinaga T; Sato A; Fujiwara T; Kiyama R
Bioorg Med Chem; 2006 Dec; 14(24):8420-9. PubMed ID: 17005407
[TBL] [Abstract][Full Text] [Related]
12. Study on the interactions between diketo-acid inhibitors and prototype foamy virus integrase-DNA complex via molecular docking and comparative molecular dynamics simulation methods.
Hu JP; He HQ; Tang DY; Sun GF; Zhang YQ; Fan J; Chang S
J Biomol Struct Dyn; 2013; 31(7):734-47. PubMed ID: 22913375
[TBL] [Abstract][Full Text] [Related]
13. HIV-1 integrase inhibition: binding sites, structure activity relationships and future perspectives.
Parrill AL
Curr Med Chem; 2003 Sep; 10(18):1811-24. PubMed ID: 12871106
[TBL] [Abstract][Full Text] [Related]
14. Structural Studies of the HIV-1 Integrase Protein: Compound Screening and Characterization of a DNA-Binding Inhibitor.
Quashie PK; Han YS; Hassounah S; Mesplède T; Wainberg MA
PLoS One; 2015; 10(6):e0128310. PubMed ID: 26046987
[TBL] [Abstract][Full Text] [Related]
15. A platform for designing HIV integrase inhibitors. Part 1: 2-hydroxy-3-heteroaryl acrylic acid derivatives as novel HIV integrase inhibitor and modeling of hydrophilic and hydrophobic pharmacophores.
Kawasuji T; Yoshinaga T; Sato A; Yodo M; Fujiwara T; Kiyama R
Bioorg Med Chem; 2006 Dec; 14(24):8430-45. PubMed ID: 17010623
[TBL] [Abstract][Full Text] [Related]
16. Structure Based Drug Design: Clinically Relevant HIV-1 Integrase Inhibitors.
Kaur M; Rawal RK; Rath G; Goyal AK
Curr Top Med Chem; 2018; 18(31):2664-2680. PubMed ID: 30659539
[TBL] [Abstract][Full Text] [Related]
17. 4-Hydroxy-5-pyrrolinone-3-carboxamide HIV-1 integrase inhibitors.
Pace P; Spieser SA; Summa V
Bioorg Med Chem Lett; 2008 Jul; 18(14):3865-9. PubMed ID: 18595690
[TBL] [Abstract][Full Text] [Related]
18. Crystal structures of the catalytic domain of HIV-1 integrase free and complexed with its metal cofactor: high level of similarity of the active site with other viral integrases.
Maignan S; Guilloteau JP; Zhou-Liu Q; Clément-Mella C; Mikol V
J Mol Biol; 1998 Sep; 282(2):359-68. PubMed ID: 9735293
[TBL] [Abstract][Full Text] [Related]
19. Active site binding modes of dimeric phloroglucinols for HIV-1 reverse transcriptase, protease and integrase.
Gupta P; Kumar R; Garg P; Singh IP
Bioorg Med Chem Lett; 2010 Aug; 20(15):4427-31. PubMed ID: 20594846
[TBL] [Abstract][Full Text] [Related]
20. New insights into the interaction between pyrrolyl diketoacids and HIV-1 integrase active site and comparison with RNase H.
Corona A; di Leva FS; Rigogliuso G; Pescatori L; Madia VN; Subra F; Delelis O; Esposito F; Cadeddu M; Costi R; Cosconati S; Novellino E; di Santo R; Tramontano E
Antiviral Res; 2016 Oct; 134():236-243. PubMed ID: 27659398
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
